Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Long-Term Investments (2017 - 2025)

Protagonist Therapeutics' Long-Term Investments history spans 6 years, with the latest figure at $78.6 million for Q4 2025.

  • For Q4 2025, Long-Term Investments fell 43.95% year-over-year to $78.6 million; the TTM value through Dec 2025 reached $78.6 million, down 43.95%, while the annual FY2025 figure was $78.6 million, 43.95% down from the prior year.
  • Long-Term Investments for Q4 2025 was $78.6 million at Protagonist Therapeutics, down from $102.7 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $140.3 million in Q4 2024 and bottomed at $2.0 million in Q3 2023.
  • The 4-year median for Long-Term Investments is $78.6 million (2025), against an average of $69.7 million.
  • The largest annual shift saw Long-Term Investments skyrocketed 5671.28% in 2024 before it crashed 43.95% in 2025.
  • A 4-year view of Long-Term Investments shows it stood at $38.2 million in 2021, then tumbled by 94.8% to $2.0 million in 2023, then surged by 6968.01% to $140.3 million in 2024, then plummeted by 43.95% to $78.6 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Long-Term Investments are $78.6 million (Q4 2025), $102.7 million (Q3 2025), and $102.5 million (Q2 2025).